drugset / Trial / NCT03654755
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized open label study to evaluate the long term safety of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
Timeline
- Start
- 2018-09-29
- Primary completion
- 2019-10-29
- Completion
- 2019-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gusacitinib | Small molecule | 40 mg | — |
| Subject | Gusacitinib | Small molecule | 60 mg | — |
| Subject | Gusacitinib | Small molecule | 80 mg | — |